GSK Forms Joint Venture With Shenzhen Neptunus Interlong Bio-Technique For Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - GlaxoSmithKline announced Nov. 21 a joint venture with Shenzhen Neptunus Interlong Bio-Technique to develop flu vaccines aimed at strains specific to China, Hong Kong and Macau